Webinar

Ground Broken: Novel Therapies to Manage Idiopathic Hypersomnia

Launch Date
07/20/2023 at 4:00 am EST
Credit Amount
0.25
Credit Expires
07/20/2024
This activity is part of a series

Faculty

Richard K. Bogan, MD, FCCP, FAASM
Associate Clinical Professor
University of South Carolina Medical School
Columbia, SC
Medical University of South Carolina
Charleston, SC
Principal, Bogan Sleep Consultants, LLC
Columbia, SC
Richard K. Bogan, MD, FCCP, FAASM

Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, SC.

Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine, and Pulmonary Diseases.

Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia, and circadian rhythm abnormality.

Anne Marie Morse, DO, FAASM
Associate Professor
Geisinger Commonwealth School of Medicine
Director, Child Neurology and Pediatric Sleep Medicine, Geisinger Medical Center
Janet Weis Children’s Hospital
Danville, PA
Anne Marie Morse, DO, FAASM

Dr. Anne Marie Morse is the Director of Child Neurology and Pediatric Sleep Medicine at Geisinger, Janet Weis Children’s Hospital. She has significant clinical and research experience and interest in children, adolescents, and adults with sleep wake disorders, particularly central disorders of hypersomnolence. In addition, her research interests extend more broadly to include investigating the relationship between sleep and neurologic and neurodevelopmental disorders. Dr Morse’s commitment to sleep health extends into the community. She has developed a school-based sleep education and surveillance program called Wake Up and Learn.  This program was developed to provide education about sleep health and perform school-based sleep screening to improve recognition of pediatric sleep disorders in middle and high school students. It has now expanded to include learners in college, medical school, and medical residency programs with a clinical and health plan delivery, called Sleep to Be Well. Dr. Morse envisions a world where sleep can be acknowledged as the vital sign of health, wellness, and performance that it is designed to be.

Explore By Section
Statement of Need Learning Objective Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

In August 2021, lower sodium oxybate (LXB) was the first treatment approved for idiopathic hypersomnia (IH). This is a breakthrough achievement; however, awareness and understanding of the new therapy, as well as other novel therapies, may be suboptimal. In data collected regarding LXB, only 8% of clinicians were aware LXB had received approval for IH pre-activity. In another pre-activity survey, 54% of clinicians were unlikely/not at all likely to use FDA-approved therapy in practice while 57% were unsure/not confident in transitioning patients from current therapy, suggesting a significant gap in knowledge regarding novel treatments. Clinicians need education on the clinically meaningful effects of LXB twice-nightly treatment for patients with IH.

In this CMEO Snack entitled, Ground Broken: Novel Therapies to Manage Idiopathic Hypersomnia, expert faculty will discuss current and novel therapies in IH, efficacy and safety data from recent clinical trials, and relevant findings from the SLEEP 2023 conference.

Learning Objective

Utilize the latest efficacy and safety data to integrate novel therapies into clinical practice to mitigate the impact of IH.

Financial Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Target Audience

Sleep specialists, primary care physicians, pulmonologists, neurologists, psychiatrists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.25

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.25

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.25

This activity is designated for 0.25 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.25

This application-based activity is approved for 0.25 contact hours (0.025 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-077-H01-P

Physician Assistants (AAPA): 0.25

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.25

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Bogan reports the following financial relationships:

Consultant: Avadel; Axsome Therapeutics, Inc.; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; Oventus; and Takeda Pharmaceuticals U.S.A., Inc.

Research Support: Apnimed; Avadel; Bayer; Bresotec Medical; Eisai Inc.; Fisher Paykel Healthcare; FRESCA Medical; Idorsia Pharmaceuticals US Inc.; Jazz Pharmaceuticals, Inc.; LivaNova; Merck & Co., Inc.; NLS Pharmaceutics; Philips; Roche; Sanofi; Sommetrics, Inc.; Suven Pharma; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals Inc.

Speakers Bureau: Eisai Inc.; Harmony Biosciences; Idorsia Pharmaceuticals US Inc.; and Jazz Pharmaceuticals, Inc.

Dr. Morse reports the following financial relationships:

Advisory Board: Alkermes; Avadel; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Grants: Coverys Community Healthcare Foundation; Jazz Pharmaceuticals, Inc.; and ResMed Foundation

Research Support: Geisinger Health Plan; Jazz Pharmaceuticals, Inc.; and UCB, Inc.

Speakers Bureau: Jazz Pharmaceuticals, Inc.

Employment: DAMM Good Sleep, LLC (CEO)

Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:

  • Christina Rivera Carpenter, PhD, RN (peer reviewer)
  • Evan Luberger (planning committee)
  • John Jones, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

 

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-211-072023-43

Ground Broken: Novel Therapies to Manage Idiopathic Hypersomnia
Event Date: 07/20/2023 at 4:00 am EST
Register

Activities in the Series

Sleep Disorders
07/20/2023 at 4:00 am EST

Too Much Sleep: Quality of Life in Patients with Idiopathic Hypersomnia

0.25
Register Learn More
Sleep Disorders
07/24/2023 at 4:00 am EST

Disrupted Sleep: Quality of Life in Patients with Narcolepsy

0.25
Register Learn More
Sleep Disorders
07/28/2023 at 4:00 am EST

Managing Cardiovascular Risk in Patients with Narcolepsy

0.25
Register Learn More